Patient-derived Organoid Drug Sensitivity Guided Treatment for Drug-resistant Recurrent Non-Small Cell Lung Cancer

This study uses tiny lab-grown tumor models (called organoids) made from a patient's own cancer tissue to predict which chemotherapy drug will work best for that individual. It is focused on patients with non-small cell lung cancer that has stopped responding to prior treatments. **You may be eligible if...** - You are 18 to 75 years old - You have non-small cell lung cancer that has returned or stopped responding to treatment - You have already received at least two systemic treatments - You are in good physical condition (ECOG score 0–1) - You have at least one tumor that can provide a tissue sample for organoid testing - Your expected survival is more than 3 months **You may NOT be eligible if...** - Your disease has not progressed after prior treatment (confirmed on imaging) - You are not well enough to tolerate further treatment Talk to your doctor to see if this trial is right for you.